Relmada Therapeutics (RLMD) Long-Term Debt Issuances (2014 - 2020)

Relmada Therapeutics (RLMD) has 7 years of Long-Term Debt Issuances data on file, last reported at $110247.0 in Q1 2020.

• On a quarterly basis, Long-Term Debt Issuances rose 28.24% year-over-year to $110247.0 in Q1 2020; TTM through Dec 2020 was $110247.0, a 77.25% decrease from a year earlier, with the FY2022 full-year figure at $50000.0, changed N/A from the prior year.
• Long-Term Debt Issuances for Q1 2020 stood at $110247.0, down from $253957.0 in the prior quarter.
• Over the last five years, Long-Term Debt Issuances for RLMD reached as high as $4.0 million in Q3 2017 and fell as low as -$6.3 million in Q1 2018.
• Historically, Long-Term Debt Issuances has averaged $91750.5 across 5 years, with a median of $85969.0 in 2019.
• Across the five-year window, Long-Term Debt Issuances surged 4439.27% in 2017 and plunged 7691.16% in 2018, its largest moves.
• Year by year, Long-Term Debt Issuances stood at $54403.0 in 2016, then jumped by 4439.27% to $2.5 million in 2017, then tumbled by 96.54% to $85466.0 in 2018, then surged by 197.14% to $253957.0 in 2019, then slumped by 56.59% to $110247.0 in 2020.
• Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $110247.0 in Q1 2020, $253957.0 in Q4 2019, and $108279.0 in Q3 2019.